b'NGS Cancer PanelsTest Name within the final 3 genes are also targeted. Coupling MyMRD - NGS Gene Panel Assay comprehensive gene coverage with enhanced depth of coverage, long read lengths, and the power of our robust MyInformatics annotation software and bioinformatics Assay Type database, MyMRD confidently and reproducibly detects mutations with a mutant allele frequency of 5x10 -3 , while Next-Generation Sequencing (NGS) some mutations, such as FLT3 ITDs, are detected at CLIA-validated assay mutation allele frequencies as low at 1x10 -3 . Method Description A completed patient consent form must be submittedIndexed whole-genome libraries are hybridized withfor each sample sent to LabPMM.MyMRD probes targeting mutation hotspots in a total of 23 genes (ASXL1 BRAF CALR CEBPA CSF3R DNMT3A FLT3 IDH1Indications for Testing IDH2 JAK2 KIT KRAS MPL NPM1 NRAS PTPN11 RUNX1 SF3B1Identify tumor-specific markers for post-treatmentSRSF2 TP53 ZRSR2 CBFB-MYH11 KMT2A RUNX1-RUNX1T1). Inmonitoring addition to targeting single nucleotide variants (SNVs) and indels in the first 21 genes, 5 structural variant breakpointsMonitor and evaluate for refractory and relapsed diseaseInterpretation TurnaroundSpecimen Requirements ShippingSpecimen Time Conditions StabilityAn interpretive14 to 21 3 mL of peripheral blood in Heparin,Ambient or Room Temp report will bebusiness days EDTA or ACD Cool; do notup to 72 issued indicating1 mL of bone marrow in Heparin,freeze hoursthe detected EDTA or ACD 2-8 C uppathogenic 1 g of purified, high qualityto 7 daysmutations and their frequenciesgenomic DNAin the interrogated sample.LabPMM Services Catalog 2021|53'